Flossbach Von Storch SE Trims Holdings in Johnson & Johnson (NYSE:JNJ)

Flossbach Von Storch SE decreased its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 0.6% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 6,488,992 shares of the company's stock after selling 40,304 shares during the period. Johnson & Johnson makes up approximately 4.7% of Flossbach Von Storch SE's holdings, making the stock its 4th largest holding. Flossbach Von Storch SE owned approximately 0.27% of Johnson & Johnson worth $1,076,134,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in JNJ. Brighton Jones LLC grew its stake in shares of Johnson & Johnson by 13.9% in the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock worth $7,502,000 after purchasing an additional 6,332 shares during the last quarter. Hudson Value Partners LLC lifted its holdings in shares of Johnson & Johnson by 2.5% during the fourth quarter. Hudson Value Partners LLC now owns 41,403 shares of the company's stock valued at $5,648,000 after purchasing an additional 1,022 shares during the last quarter. Proficio Capital Partners LLC lifted its holdings in shares of Johnson & Johnson by 22.0% during the fourth quarter. Proficio Capital Partners LLC now owns 19,951 shares of the company's stock valued at $2,885,000 after purchasing an additional 3,594 shares during the last quarter. Raymond James Financial Inc. purchased a new position in shares of Johnson & Johnson during the fourth quarter valued at approximately $1,339,878,000. Finally, Natural Investments LLC purchased a new position in shares of Johnson & Johnson during the fourth quarter valued at approximately $986,000. Hedge funds and other institutional investors own 69.55% of the company's stock.

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock traded down $0.82 during trading hours on Friday, hitting $156.87. The company's stock had a trading volume of 7,866,488 shares, compared to its average volume of 8,077,942. The business has a 50 day moving average price of $153.75 and a two-hundred day moving average price of $154.55. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $169.99. The company has a market cap of $377.44 billion, a PE ratio of 17.45, a PEG ratio of 2.14 and a beta of 0.41. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, topping analysts' consensus estimates of $2.59 by $0.18. The company had revenue of $21.89 billion for the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. Analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th were given a $1.30 dividend. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.31%. The ex-dividend date of this dividend was Tuesday, May 27th. Johnson & Johnson's payout ratio is currently 57.84%.

Analyst Upgrades and Downgrades

JNJ has been the subject of several recent research reports. Sanford C. Bernstein reiterated a "market perform" rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Royal Bank Of Canada restated an "outperform" rating and issued a $181.00 price objective on shares of Johnson & Johnson in a report on Thursday, June 5th. Benchmark upgraded shares of Johnson & Johnson to a "strong-buy" rating in a report on Thursday, April 24th. Guggenheim restated a "neutral" rating on shares of Johnson & Johnson in a report on Wednesday, April 2nd. Finally, Wall Street Zen upgraded shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research note on Saturday, June 21st. Eleven analysts have rated the stock with a hold rating, seven have given a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $171.00.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.